Business
MedMira Awarded U.S. Army Contract to Develop and Commercialize A Multi-Marker Hepatitis B Core Antibody Rapid Test
Jul. 4, 2011 (Canada NewsWire Group) -- HALIFAX, July 4, 2011 /CNW/ - MedMira Inc., ("Me...
About this update from Medmira Inc.
[{"type":"text","content":"\n\n\n Jul. 4, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nHALIFAX, July 4, 2011 /CNW/ - MedMira Inc., ("MedMira") (TSXV: MIR)\n (NASDAQ: MMIRF), a developer and marketer of rapid diagnostic\n technology and solutions, today announced it has been awarded a U.S.\n Army Medical Research Acquisition Activity (USAMRAA) contract, valued\n at USD$2,278,192, to develop and commercialize a multi-marker rapid\n test for the detection of the Hepatitis B Core IgG and IgM\n antibodies. Under contract number W81XWH-11-C-0090 the U.S. Army will\n fund all development costs and associated fees in obtaining a U.S. Food\n and Drug Administration (FDA) premarket approval (PMA) for this new\n rapid test.\n\n\nThe multi-year contract involves a comprehensive scope of work in which\n MedMira will advance and commercialize a rapid test that will detect\n Hepatitis B core IgG and IgM antibodies within three minutes.  The\n Company will perform in-house validation and evaluations, take the new\n test through clinical trials and obtain FDA approval.  Once approved,\n the product will be supplied by MedMira directly to the U.S. Army and\n to other customers through typical distribution sales channels.\n\n\n"We are excited to receive the awarded contract and to work with the\n U.S. Army in advancing the health services provided to those serving in\n the armed forces.  The work that will be undertaken within this project\n is wholly aligned with MedMira's core compet...